MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MOLECULAR PARTNERS AG
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 12, 2026
$3.66+0.10 (+2.81%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
8.9%
4M of 40M shares
Institutional holders
5
2 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BVF Partners L.P. | 9,888,592 | 24.50% | 13D (active) amendment | Oct 25, 2024 |
| Suvretta Capital Management, LLC | 4,284,806 | 10.60% | 13G (passive) | Jun 15, 2021 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,144,607 | 5.80% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MOLN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2,221,494 | 5.50% | $8.60M | – | 0.16% |
| Bvf Inc/Il | 1,353,968 | 3.35% | $5.15M | – | 0.13% |
| Citadel Advisors LLC | 17,179 | 0.04% | $65.28K | New | 0.00% |
| Morgan Stanley | 367 | 0.00% | $1.42K | – | 0.00% |
| UBS Group AG | 279 | 0.00% | $1.08K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 5 | 4M | 8.9% | 2 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 4 | 4M | 8.9% | 0 / 1 | 0 / 2 | 0M | 0M |
| Q4 2025 | 6 | 4M | 8.9% | 1 / 0 | 2 / 1 | 0M | 0M |
| Q3 2025 | 6 | 4M | 8.9% | 0 / 1 | 1 / 0 | 0M | 0M |
| Q2 2025 | 6 | 4M | 8.9% | 1 / 1 | 0 / 1 | 0M | 0M |
| Q1 2025 | 6 | 4M | 8.9% | 1 / 0 | 1 / 0 | 0M | 0M |
| Q4 2024 | 5 | 4M | 8.9% | 0 / 3 | 1 / 0 | 3M | 0M |
| Q3 2024 | 5 | 1M | 2.1% | 0 / 2 | 0 / 3 | 0M | 0M |
| Q2 2024 | 8 | 1M | 2.1% | 1 / 1 | 2 / 1 | 0M | 0M |
| Q1 2024 | 8 | 1M | 2.3% | 2 / 1 | 0 / 2 | 0M | 0M |
| Q4 2023 | 8 | 1M | 2.4% | 1 / 1 | 1 / 0 | 0M | 0M |
| Q3 2023 | 7 | 1M | 2.4% | 1 / 1 | 1 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MOLN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 1,070 | 0.00% | $4.45K | 0.00% | May 31, 2026 |